{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:50:10Z","timestamp":1788522610773,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"DOI":"10.1093\/rheumatology\/kex474","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T07:09:12Z","timestamp":1515740952000},"page":"688-693","source":"Crossref","is-referenced-by-count":42,"title":["Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study"],"prefix":"10.1093","volume":"57","author":[{"given":"Alejandro","family":"Balsa","sequence":"first","affiliation":[{"name":"Department of Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimon","family":"Sanmarti","sequence":"additional","affiliation":[{"name":"Arthritis Unit, Department of Rheumatology, Hospital Clinic de Barcelona and IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Rosas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Marina Baixa, Villajoyosa, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Martin","sequence":"additional","affiliation":[{"name":"Biostatistics, Pfizer Espa\u00f1a, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cabez","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Espa\u00f1a, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"Inflammation Rheumatology, Medical Department, Pfizer SLU, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Montoro","sequence":"additional","affiliation":[{"name":"Inflammation Rheumatology, Medical Department, Pfizer SLU, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"key":"key\n\t\t\t\t20180326035333_kex474-B1","first-page":"1","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180326035333_kex474-B2","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180326035333_kex474-B3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180326035333_kex474-B4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0000000000000229","article-title":"An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies","volume":"21","author":"Bandres Ciga","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t20180326035333_kex474-B5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14712598.2016.1118457","article-title":"Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis","volume":"16","author":"Mok","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"key\n\t\t\t\t20180326035333_kex474-B6","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180326035333_kex474-B7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180326035333_kex474-B8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14740338.2016.1112375","article-title":"Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?","volume":"15","author":"Murdaca","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"key\n\t\t\t\t20180326035333_kex474-B9","first-page":"1896","article-title":"Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration","volume":"35","author":"Toki","year":"2008","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180326035333_kex474-B10","author":"Progenica Biopharma SA","year":"2017"},{"key":"key\n\t\t\t\t20180326035333_kex474-B11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","article-title":"Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180326035333_kex474-B12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"key":"key\n\t\t\t\t20180326035333_kex474-B13","first-page":"7","article-title":"Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins","volume":"9","author":"Benucci","year":"2015","journal-title":"Biologics"},{"key":"key\n\t\t\t\t20180326035333_kex474-B14","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2012-202407","article-title":"Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation","volume":"72","author":"van Schouwenburg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180326035333_kex474-B15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180326035333_kex474-B16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180326035333_kex474-B17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4331\/wjbc.v3.i4.73","article-title":"Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges","volume":"3","author":"Vugmeyster","year":"2012","journal-title":"World J Biol Chem"},{"key":"key\n\t\t\t\t20180326035333_kex474-B18","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203893","article-title":"Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180326035333_kex474-B19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","article-title":"Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility","volume":"43","author":"Wadhwa","year":"2015","journal-title":"Biologicals"},{"key":"key\n\t\t\t\t20180326035333_kex474-B20","doi-asserted-by":"crossref","DOI":"10.1002\/9781118075685","volume-title":"Detection and quantification of antibodies to biopharmaceuticals: practical and applied considerations","author":"Tovey","year":"2011"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/4\/688\/24459404\/kex474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T05:07:28Z","timestamp":1570597648000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/4\/688\/4818104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,1,19]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kex474","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2018,1,19]]}}}